ASH 2021 Post-Conference Perspectives: Updates in Multiple Myeloma

Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.

Expert perspective on results from the MASTER trial, which analyzed dara-KRd as frontline therapy with MRD-adapted use in newly diagnosed multiple myeloma.

Insight on the survival benefit seen with frontline daratumumab-based regimens in patients with transplant-ineligible multiple myeloma.

Rafael Fonseca, MD, reviews data on rescue isatuximab from the ASH 2021 annual meeting and discusses use of best therapies up front.

Taking into account data from the ASH 2021 annual meeting, Rafael Fonseca, MD, reviews his current approaches to frontline therapy for patients with multiple myeloma.

Updated results from the GRIFFIN trial in newly diagnosed multiple myeloma, including consideration for frontline 4-drug regimens and depth of response.

Looking toward the future management of patients with multiple myeloma, Rafael Fonseca, MD, shares excitement for novel therapeutic strategies.

Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.